Gene Expression Assays of Natural and Mutant Type I IFN
Project Number1R43CA101609-01A1
Contact PI/Project LeaderTAUB, FLOYD E
Awardee OrganizationLIFETIME PHARMACEUTICALS, INC.
Description
Abstract Text
DESCRIPTION (provided by applicant): Microarray analysis, in combination with new statistical tools, is a powerful technology for studying gene expression. Dr. He has successfully applied this approach in his lab to analyze IFN-induced expression in human PBMCs. Dr. Pontzer has created single amino acid (AA) substituted IFNs that have been found to have unique combinations of biologic activities. The application of microarray analysis to these novel IFNs may provide information concerning the genes involved in the anti-viral activity (AV), anti-proliferative activity (AP) and toxicity. Specifically Dr. Pontzer has reported several single AA substitutions that insert IFN alpha sequence, into IFN tau (a non-toxic type 1 IFN). The collection of mutants is reported to separate AP, AV, and toxicity. One substitution (LFN tau 26 P:L) is reported to produce an IFN-tau with good AV activity and AP equivalent to IFN-alpha, but not the toxicity typical of IFN-alpha. Others have low AV compared to their AP. This work will extend our understanding of IFN action, provide independent confirmation of biologic properties of these novel interferons, and provide a tool for developing and testing medically important IFNs and IFN like drugs. At least one novel IFN already synthesized is one such candidate molecule.
No Sub Projects information available for 1R43CA101609-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R43CA101609-01A1
Patents
No Patents information available for 1R43CA101609-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R43CA101609-01A1
Clinical Studies
No Clinical Studies information available for 1R43CA101609-01A1
News and More
Related News Releases
No news release information available for 1R43CA101609-01A1
History
No Historical information available for 1R43CA101609-01A1
Similar Projects
No Similar Projects information available for 1R43CA101609-01A1